Tag: CRDMO
Syngene acquires its first manufacturing facility in the US
Biologics drug substance facility in Baltimore expected to enhance global innovator flexibility
India’s CRDMO sector growth potential at $22-$25 billion by 2035: BCG-IPSO...
Report states that India’s CRDMO sector is poised for rapid growth with strong fundamentals and global realignments, focusing on leading-edge science and technology
Jubilant Biosys seals deal with Pierre Fabre SA
To acquire R&D center at Saint-Julien-en-Genevois, France
Aragen secures $100 Mn investment from Quadria Capital
With Quadria acquiring a minority stake in the company, investment will fund expansion to meet rising demand for CRDMO services
Aragen receives Platinum Medal from EcoVadis for its sustainability initiatives
First Indian company to receive this highest global sustainability recognition
Anthem Biosciences files DRHP for Rs 3,395 crore IPO
The equity shares of Bangalore based company are proposed to be listed on BSE and NSE
Jubilant Biosys to expand its footprint in Europe, add drug discovery...
Through a series of collaborative and acquisition deals, company aims to develop a unique delivery model tailored for its customers
Sai Life Sciences releases 2024 Sustainability Report highlighting major climate action...
The 2024 report emphasizes Sai Life Sciences' strides in renewable energy, GHG emissions reduction, social responsibility, and commitment to ESG goals
Aragen becomes first Indian CRDMO to secure SBTi approval for emission...
Aragen Life Sciences commits to cutting greenhouse gas emissions by 50% by 2033 and achieving net-zero emissions by 2050
Aragen & Getinge’s SUPR bioreactors scale antibody production from 2L to...
Successful GMP validation of 50L and 250L SUPRs promises to transform biopharmaceutical manufacturing, offering seamless scale-up from research to production